These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9383724)

  • 21. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
    Zapater P; Horga JF
    Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine.
    Yacobi A; Zlotnick S; Colaizzi JL; Moros D; Masson E; Abolfathi Z; LeBel M; Mehta R; Golander Y; Levitt B
    Clin Pharmacol Ther; 1999 Apr; 65(4):389-94. PubMed ID: 10223775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
    Marzo A; Balant LP
    Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of in vitro-in vivo equivalence of highly variable drugs - a generic product development perspective.
    Pathak SM; Aggarwal D; Venkateswarlu V
    Pharm Dev Technol; 2014 Jun; 19(4):401-10. PubMed ID: 23607272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach.
    Idkaidek NM; Al-Ghazawi A; Najib NM
    Biopharm Drug Dispos; 2004 Dec; 25(9):367-72. PubMed ID: 15495146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The new European Medicines Agency guideline on the investigation of bioequivalence.
    Morais JA; Lobato Mdo R
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioequivalence and narrow therapeutic index drugs.
    Benet LZ; Goyan JE
    Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2011 Nov; 44(4):497-505. PubMed ID: 21945487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D; Frýbortová K; Rabisková M; Danecková H
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioequivalence study designs for generic solid oral anticancer drug products: scientific and regulatory considerations.
    Kaur P; Chaurasia CS; Davit BM; Conner DP
    J Clin Pharmacol; 2013 Dec; 53(12):1252-60. PubMed ID: 23996908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
    Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
    Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of moment-based and probability-based criteria for assessment of follow-on biologics.
    Chow SC; Hsieh TC; Chi E; Yang J
    J Biopharm Stat; 2010 Jan; 20(1):31-45. PubMed ID: 20077247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel bioequivalence approach for narrow therapeutic index drugs.
    Yu LX; Jiang W; Zhang X; Lionberger R; Makhlouf F; Schuirmann DJ; Muldowney L; Chen ML; Davit B; Conner D; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):286-91. PubMed ID: 25669762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M
    Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability and bioequivalence: average, population and/or individual.
    Colburn WA; Keefe DL
    J Clin Pharmacol; 2000 Jun; 40(6):559-60. PubMed ID: 10868304
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.